„Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders“. Lancet. 365-jild, № 9464. 2005. 1054–61-bet. doi:10.1016/S0140-6736(05)71142-9. PMID15781101.
„Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis“. Cancer Cell. 7-jild, № 4. 2005. 387–97-bet. doi:10.1016/j.ccr.2005.03.023. PMID15837627.
„Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders“. Lancet. 365-jild, № 9464. 2005. 1054–61-bet. doi:10.1016/S0140-6736(05)71142-9. PMID15781101.
„Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis“. Cancer Cell. 7-jild, № 4. 2005. 387–97-bet. doi:10.1016/j.ccr.2005.03.023. PMID15837627.